{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:32:31Z","timestamp":1762864351179},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,3,15]]},"DOI":"10.1086\/319378","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T13:32:28Z","timestamp":1027690348000},"page":"S64-S71","source":"Crossref","is-referenced-by-count":13,"title":["Clinical Perspectives on New Antimicrobials: Focus on Fluoroquinolones"],"prefix":"10.1093","volume":"32","author":[{"given":"David A.","family":"Talan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2001,3,15]]},"reference":[{"key":"key\n\t\t\t\t20171014014412_R1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1086\/515107","article-title":"Introduction: acute respiratory tract infections\u2014the forgotten pandemic","volume":"28","author":"Shann","year":"1999","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014014412_R2","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199512143332408","article-title":"Community-acquired pneumonia","volume":"333","author":"Bartlett","year":"1995","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014014412_R3","first-page":"S232","article-title":"Epidemiology of community-acquired pneumonia","volume":"4","author":"Marston","year":"1995","journal-title":"Infect Dis Clin Pract"},{"key":"key\n\t\t\t\t20171014014412_R4","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0149-2918(98)80144-6","article-title":"The cost of treating community-acquired pneumonia","volume":"20","author":"Niederman","year":"1998","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20171014014412_R5","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0149-2918(00)88310-1","article-title":"Treatment cost of acute exacerbations of chronic bronchitis","volume":"21","author":"Niederman","year":"1999","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20171014014412_R6","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0091-6749(99)70464-1","article-title":"Healthcare expenditures for sinusitis in 1996: contributions of asthma, rhinitis, and other airway disorders","volume":"103","author":"Ray","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"key\n\t\t\t\t20171014014412_R7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00063198-199605000-00005","article-title":"Severe community-acquired pneumonia","volume":"2","author":"Cassiere","year":"1996","journal-title":"Curr Opin Pulm Med"},{"key":"key\n\t\t\t\t20171014014412_R8","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1097\/00003246-199711000-00026","article-title":"Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent","volume":"25","author":"Rello","year":"1997","journal-title":"Crit Care Med"},{"key":"key\n\t\t\t\t20171014014412_R9","first-page":"465","article-title":"Role of infection in chronic bronchitis","volume":"113","author":"Gump","year":"1976","journal-title":"Am Rev Respir Dis"},{"key":"key\n\t\t\t\t20171014014412_R10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1378\/chest.108.2_Supplement.35S","article-title":"Community-acquired pneumonia. Etiology, epidemiology, and treatment","volume":"108","author":"Mandell","year":"1995","journal-title":"Chest"},{"key":"key\n\t\t\t\t20171014014412_R11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1378\/chest.108.2_Supplement.43S","article-title":"Epidemiology and treatment of chronic bronchitis and its exacerbations","volume":"108","author":"Ball","year":"1995","journal-title":"Chest"},{"key":"key\n\t\t\t\t20171014014412_R12","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1164\/ajrccm\/148.5.1418","article-title":"Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association","volume":"148","author":"Niederman","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"key\n\t\t\t\t20171014014412_R13","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1086\/513953","article-title":"Community-acquired pneumonia in adults: guidelines for management. Infectious Diseases Society of America","volume":"26","author":"Bartlett","year":"1998","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014014412_R14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1378\/chest.115.suppl_1.9S","article-title":"Treatment of community-acquired pneumonia\u2014IDSA guidelines. Infectious Diseases Society of America","volume":"115","author":"Bernstein","year":"1999","journal-title":"Chest"},{"key":"key\n\t\t\t\t20171014014412_R15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3201\/eid0506.990603","article-title":"Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997\u201398","volume":"5","author":"Doern","year":"1999","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20171014014412_R16","first-page":"656","article-title":"Geographic variation in penicillin resistance in Streptococcus pneumoniae: selected sites, United States, 1997","volume":"48","author":"Gelling","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20171014014412_R17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJM199907223410403","article-title":"Decreased susceptibility of Streptococcus pneumoniae from across Canada to fluoroquinolones","volume":"341","author":"Chen","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014014412_R18","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/AAC.41.2.292","article-title":"Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of \u03b2-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study","volume":"41","author":"Doern","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014014412_R19","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1128\/AAC.40.12.2884","article-title":"Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study","volume":"40","author":"Doern","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014014412_R20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1128\/AAC.43.2.385","article-title":"Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997)","volume":"43","author":"Doern","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014014412_R21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/jac\/44.6.749","article-title":"Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997\u20131998","volume":"44","author":"Thornsberry","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014014412_R22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1056\/NEJM199408113310607","article-title":"Management of infections caused by antibiotic-resistant Streptococcus pneumoniae","volume":"331","author":"Friedland","year":"1994","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014014412_R23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/00365549709019038","article-title":"Choice of an oral \u03b2-lactam antibiotic for infections due to penicillin-resistant Streptococcus pneumoniae","volume":"29","author":"Goldstein","year":"1997","journal-title":"Scand J Infect Dis"},{"key":"key\n\t\t\t\t20171014014412_R24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1056\/NEJM198707023170104","article-title":"Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci","volume":"317","author":"Pallares","year":"1987","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014014412_R25","first-page":"65","article-title":"Failure of macrolide therapy in patients with bacteremia due to macrolide-resistant Streptococcus pneumoniae [abstract 7.09]","volume-title":"Programs and abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolinones (Seville, Spain)","author":"Garau","year":"2000"},{"key":"key\n\t\t\t\t20171014014412_R26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/mdr.1995.1.1","article-title":"The prospects of treatment failure in the chemotherapy of infectious diseases in the 1990s","volume":"1","author":"Armstrong","year":"1995","journal-title":"Microb Drug Resist"},{"key":"key\n\t\t\t\t20171014014412_R27","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/clinids\/18.2.188","article-title":"Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review","volume":"18","author":"John","year":"1994","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014014412_R28","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0022-3476(95)70415-9","article-title":"Bacteriologic failure of amoxicillin-clavulanate in treatment of acute otitis media caused by nontypeable Haemophilus influenzae","volume":"126","author":"Patel","year":"1995","journal-title":"J Pediatr"},{"key":"key\n\t\t\t\t20171014014412_R29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000030344","article-title":"Genotypic evolution in a quinolone-resistant Neisseria gonorrhoeae isolate from a patient with clinical failure of levofloxacin treatment","volume":"62","author":"Tanaka","year":"1999","journal-title":"Urol Int"},{"key":"key\n\t\t\t\t20171014014412_R30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00007435-199705000-00002","article-title":"Fluoroquinolone treatment failure in gonorrhea. Emergence of a Neisseria gonorrhoeae strain with enhanced resistance to fluoroquinolones","volume":"24","author":"Deguchi","year":"1997","journal-title":"Sex Transm Dis"},{"key":"key\n\t\t\t\t20171014014412_R31","first-page":"111","article-title":"Three levofloxacin treatment failures of pneumococcal respiratory tract infections [abstract 825]","volume-title":"Programs and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco)","author":"Fishman","year":"1999"},{"key":"key\n\t\t\t\t20171014014412_R32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0732-8893(98)00083-2","article-title":"Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: report from the SENTRY Antimicrobial Surveillance Program (1998)","volume":"32","author":"DiPersio","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014014412_R33","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1086\/313557","article-title":"Fatal meningitis due to levofloxacinresistant Streptococcus pneumoniae","volume":"29","author":"Wortmann","year":"1999","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014014412_R34","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jama.281.8.736","article-title":"Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women","volume":"281","author":"Gupta","year":"1999","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20171014014412_R35","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","article-title":"Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women","volume":"283","author":"Talan","year":"2000","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20171014014412_R36","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/BF01709543","article-title":"Severe community-acquired pneumonia in ICUs: prospective validation of a prognostic score","volume":"22","author":"Leroy","year":"1996","journal-title":"Intensive Care Med"},{"key":"key\n\t\t\t\t20171014014412_R37","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2958.1995.tb02369.x","article-title":"The twisted \u201clife\u201d of DNA in the cell: bacterial topoisomerases","volume":"15","author":"Luttinger","year":"1995","journal-title":"Mol Microbiol"},{"key":"key\n\t\t\t\t20171014014412_R38","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1128\/AAC.40.4.879","article-title":"Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli","volume":"40","author":"Heisig","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014014412_R39","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1128\/AAC.40.12.2760","article-title":"High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA","volume":"40","author":"Janoir","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014014412_R40","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1128\/AAC.41.12.2733","article-title":"Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus","volume":"41","author":"Kaatz","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014014412_R41","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/AAC.43.1.187","article-title":"Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae","volume":"43","author":"Gill","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014014412_R42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00002018-199921050-00005","article-title":"Comparative tolerability of the newer fluoroquinolone antibacterials","volume":"21","author":"Ball","year":"1999","journal-title":"Drug Saf"},{"key":"key\n\t\t\t\t20171014014412_R43","doi-asserted-by":"crossref","first-page":"13991","DOI":"10.1073\/pnas.94.25.13991","article-title":"DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance","volume":"94","author":"Zhao","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20171014014412_R44","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1128\/AAC.42.11.2978","article-title":"Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance","volume":"42","author":"Dong","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014014412_R45","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1128\/AAC.43.6.1508","article-title":"Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration","volume":"43","author":"Wise","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl B","key":"key\n\t\t\t\t20171014014412_R46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jac\/43.suppl_2.69","article-title":"Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species","volume":"43","author":"Siefert","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014014412_R47","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/jac\/44.6.835","article-title":"Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy","volume":"44","author":"Soman","year":"1999","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl B","key":"key\n\t\t\t\t20171014014412_R48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jac\/43.suppl_2.83","article-title":"Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man","volume":"43","author":"Stass","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014014412_R49","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0732-8893(98)00022-4","article-title":"Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains","volume":"31","author":"Biedenbach","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl B","key":"key\n\t\t\t\t20171014014412_R50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jac\/43.suppl_2.13","article-title":"Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates. Austrian Bacterial Surveillance Network","volume":"43","author":"Buxbaum","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014014412_R51","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1159\/000239474","article-title":"In vitro activity of BAY 12-8039, a new 8-methoxyquinolone","volume":"42","author":"Dalhoff","year":"1996","journal-title":"Chemotherapy"},{"key":"key\n\t\t\t\t20171014014412_R52","first-page":"83","article-title":"Fluoroquinolones for the treatment of community-acquired pneumonia [abstract 44.009]","volume-title":"Programs and abstracts of the 9th International Congress on Infectious Diseases (Buenos Aires)","author":"Campbell","year":"2000"},{"key":"key\n\t\t\t\t20171014014412_R53","first-page":"748","article-title":"Efficacy and safety of moxifloxacin vs. clarithromycin for the treatment of community-acquired pneumonia","volume":"16","author":"Fogarty","year":"1999","journal-title":"Infect Med"},{"key":"key\n\t\t\t\t20171014014412_R54","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/00003495-199957030-00007","article-title":"Moxifloxacin","volume":"57","author":"Balfour","year":"1999","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20171014014412_R55","first-page":"44","article-title":"The role of moxifloxacin, other new fluoroquinolones, and standard treatments for acute exacerbations of chronic bronchitis [abstract 14.007]","volume-title":"Programs and Abstracts of the 9th International Congress on Infectious Diseases (Buenos Aires)","author":"Anzueto","year":"2000"},{"key":"key\n\t\t\t\t20171014014412_R56","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/jac\/44.4.501","article-title":"Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis","volume":"44","author":"Wilson","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014014412_R57","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/rmed.1999.0708","article-title":"Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis","volume":"94","author":"Chodosh","year":"2000","journal-title":"Respir Med"},{"key":"key\n\t\t\t\t20171014014412_R58","first-page":"174","article-title":"Clinical needs in the millennium\u2014the role of moxifloxacin","volume-title":"Proceedings of the First International Moxifloxacin Symposium","author":"Hampel","year":"1999"},{"key":"key\n\t\t\t\t20171014014412_R59","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0149-2918(99)80046-0","article-title":"Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Sinusitis Infection Study Group","volume":"21","author":"Burke","year":"1999","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20171014014412_R60","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/rmed.1999.0769","article-title":"A comparison of the safety and efficacy of moxifloxacin and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. Sinusitis Study Group","volume":"94","author":"Siegert","year":"2000","journal-title":"Respir Med"},{"key":"key\n\t\t\t\t20171014014412_R61","first-page":"303","article-title":"The efficacy and tolerability of moxifloxacin compared to trovafloxacin in the treatment of acute sinusitis","volume":"17","author":"Baz","year":"1999","journal-title":"Todays Ther Trends"},{"key":"key\n\t\t\t\t20171014014412_R62","first-page":"205","article-title":"Moxifloxacin: a review of its safety profile based on worldwide clinical trials","volume":"18","author":"Church","year":"2000","journal-title":"Todays Ther Trends"},{"key":"key\n\t\t\t\t20171014014412_R63","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00044011-199917050-00004","article-title":"A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone and its potential relation to therapeutic efficacy","volume":"17","author":"Wise","year":"1999","journal-title":"Clin Drug Invest"},{"key":"key\n\t\t\t\t20171014014412_R64","first-page":"A5","article-title":"Does appropriate antibiotic treatment influence outcome in community-acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis? Forum on respiratory infections","volume":"Suppl A","author":"Niederman","year":"2000","journal-title":"Respir Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/32\/Supplement_1\/S64\/20904005\/32-Supplement_1-S64.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T23:01:15Z","timestamp":1583276475000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/32\/Supplement_1\/S64\/297999\/Clinical-Perspectives-on-New-Antimicrobials-Focus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3,15]]},"references-count":64,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2001,3,15]]},"published-print":{"date-parts":[[2001,3,15]]}},"URL":"https:\/\/doi.org\/10.1086\/319378","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2001,3,15]]},"published":{"date-parts":[[2001,3,15]]}}}